Dedicated to the R&D and Application of Next-Generation cellular immunotherapy Significant Advances in the Development of NK and CAR-NK Immunotherapy Products
More +
Overcome Multiple Technical Challenges Possesses numerous invention patents.
More +
National High-Tech Enterprise Zhongguancun High-Tech Enterprise Beijing Innovative SME
More +
Beijing Gene MiNK Biotechnology Co., Ltd
Beijing Gene MiNK Biotechnology Co., Ltd. is an innovative biopharmaceutical company focused on the research and development of immune cell-based therapies. Founded in December 2021 by two US-returned scientists, the company has secured Seed, Angel, and Series A funding. Our pipeline currently comprises six novel NK and CAR-NK cell-based therapeutic candidates. Notably, two candidates have received IND clearances from both: China's National Medical Products Administration (NMPA/CDE) and the US Food and Drug Administration (FDA).These therapies are being developed for multiple high-need indications, including:Advanced-stage cancers: Leukemia, Lung Cancer, Ovarian Cancer, Breast Cancer, and Autoimmune diseases.
Series A funding
More Invention Patents
Lab Area
100% objective response rate (ORR)
Overcome two major technical difficulties in the industry
Serum-free, scalable NK cell manufacturing platform enabling high-yield production of clinical-grade therapies.
Single batch yields 100-1000 clinical doses
Significantly reducing COGS
Significantly improve the transduction rate of CAR-NK cells
Achieves substantial enhancement of CAR transduction efficiency in NK cells CAR positive cell ≥90%
Immune Cell Therapy (CAR-NK)
Cell Source: CAR-NK cells from healthy blood donors
Serum-free amplification, up to300,000 times
High efficiency and stable CAR-NK cell positive rate:90%CAR+
Multiple CAR sequences with independent intellectual property rights
Covered diseases include: hematological tumors (such as CLL, ALL, MCL), multiple myeloma, solid tumors (breast cancer, ovarian cancer, lung cancer, pancreatic cancer, prostate cancer, glioma, etc.), autoimmune diseases, etc.
Beijing Gene MiNK Biotechnology Invention Patents
Technical Barriers Owned by the Company
Beijing Gene MiNK Biotechnology has solved many industry technical difficulties in the whole process and obtained multiple invention patents
Invention patents are owned in important aspects of NK and CAR-NK cell preparation
Independent intellectual property rights, no "bottleneck" problems
The preparation process has achieved domestic substitution
Thoroughly build our industry barriers and consolidate our industry position
Beijing Gene MiNK Biotechnology Product Pipeline
Cell Source: CAR-NK cells from healthy blood donors
Learn MoreNews & Blog
2022-07-28
Online Message
Please leave your needs and suggestions, and we will contact you as soon as possible!
Quick Navigation
Contact Information
Room 401, Unit 1, Building 2, No. 25, Jinghai Fourth Road, Beijing Economic and Technological Development Area, Beijing (Beijing Pilot Free Trade Zone, High-end Industrial Zone, Yizhuang Group)
Beijing Gene MiNK Biotechnology Co., Ltd